Literature DB >> 1938976

Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.

S L McElroy1, E C Dessain, H G Pope, J O Cole, P E Keck, F R Frankenberg, H G Aizley, S O'Brien.   

Abstract

BACKGROUND: Although growing research indicates that the atypical antipsychotic agent clozapine is effective in patients with schizophrenia, little is known about the efficacy of clozapine in patients with schizoaffective disorder or psychotic mood disorders. The purpose of this study was to assess whether or not clozapine is effective in some patients with schizoaffective disorder or psychotic mood disorders.
METHOD: By surveying treating clinicians and chart data, we assessed treatment response in 85 consecutive patients, including 39 with schizophrenia, 25 with schizoaffective disorder, and 14 with bipolar disorder with psychotic features, who received clozapine for at least 6 weeks at our center.
RESULTS: All patients were either inadequately responsive to or unable to tolerate standard somatic therapies. Compared to patients with schizophrenia, patients with schizoaffective disorder and bipolar disorder with psychotic features displayed significantly higher response rates to clozapine.
CONCLUSION: Clozapine may be a useful drug in the treatment of patients with schizoaffective disorder or psychotic mood disorders who are treatment resistant or intolerant of side effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1938976

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

1.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

2.  Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis.

Authors:  Todd S Woodward; Kwanghee Jung; Geoffrey N Smith; Heungsun Hwang; Alasdair M Barr; Ric M Procyshyn; Sean W Flynn; Mark van der Gaag; William G Honer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-15       Impact factor: 5.270

Review 3.  Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.

Authors:  J M Kane
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 4.  Factors associated with response to clozapine in schizophrenia: a review.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Haruo Kashima
Journal:  Psychopharmacol Bull       Date:  2011

Review 5.  Pharmacologic treatment of geriatric mania.

Authors:  William M McDonald; John Wermager
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

6.  Effects of chronic clozapine administration on markers of arachidonic acid cascade and synaptic integrity in rat brain.

Authors:  Hyung-Wook Kim; Yewon Cheon; Hiren R Modi; Stanley I Rapoport; Jagadeesh S Rao
Journal:  Psychopharmacology (Berl)       Date:  2012-03-14       Impact factor: 4.530

7.  Low doses of clozapine may stabilize treatment-resistant bipolar patients.

Authors:  Bettina S Fehr; M Erkan Ozcan; Trisha Suppes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

8.  Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects.

Authors:  A S Gibbons; E Scarr; C McLean; S Sundram; B Dean
Journal:  J Affect Disord       Date:  2008-12-21       Impact factor: 4.839

Review 9.  Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series.

Authors:  Cana Aksoy Poyraz; Şenol Turan; Ömer Faruk Demirel; Nazife Gamze Usta Sağlam; Nazım Yıldız; Alaattin Duran
Journal:  Ther Adv Psychopharmacol       Date:  2015-08

10.  Predictors of response in a sample of treatment-resistant psychotic patients on clozapine.

Authors:  Antonio Ciapparelli; Francesca Ducci; Claudia Carmassi; Marina Carlini; Rosemma Paggini; Mario Catena; Matteo Bottai; Liliana Dell'Osso
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-10       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.